Lisata Therapeutics (NASDAQ:LSTA) Stock Rating Lowered by Zacks Research

Lisata Therapeutics (NASDAQ:LSTA) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Wednesday, October 8th. Brookline Capital Management boosted their target price on shares of Lisata Therapeutics from $20.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, July 15th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Lisata Therapeutics in a research report on Thursday, August 21st. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $23.50.

Lisata Therapeutics Price Performance

Shares of LSTA stock traded up $0.04 during mid-day trading on Monday, hitting $2.14. The company had a trading volume of 32,261 shares, compared to its average volume of 42,481. The company has a market capitalization of $18.74 million, a P/E ratio of -0.96 and a beta of 1.01. The stock’s 50 day moving average price is $2.40 and its 200-day moving average price is $2.50. Lisata Therapeutics has a 52-week low of $1.87 and a 52-week high of $4.20.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.05. On average, equities research analysts expect that Lisata Therapeutics will post -2.66 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lisata Therapeutics stock. Ground Swell Capital LLC purchased a new stake in Lisata Therapeutics, Inc. (NASDAQ:LSTA) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 23,774 shares of the company’s stock, valued at approximately $62,000. Ground Swell Capital LLC owned approximately 0.27% of Lisata Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.